HALO HALOZYME THERAPEUTICS, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1159036 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY45.0%
TTM net income YoY-18.5%
TTM EPS YoY-15.6%
Revenue 3-yr CAGR32.2%
Net income 3-yr CAGR24.1%
Margins
Gross margin82.3%
Operating margin37.4%
Net margin26.9%
FCF margin49.1%
EBITDA margin38.3%
Returns
ROE216.4%
ROA17.0%
ROIC (approx.)26.6%
Asset turnover0.63x
Leverage & solvency
Liabilities / assets101.6%
Debt / equity—
Current ratio3.88x
Interest coverage30.58x
Cash quality & payout
Operating cash flow / net income1.85x
Accruals ratio-14.5%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.40B | $1.02B | $829.25M | $660.12M | $443.31M |
| Cost of revenue | $228.77M | $159.42M | $192.36M | $139.30M | $81.41M |
| Gross profit | $1.17B | $855.91M | $636.89M | $520.81M | $361.90M |
| R&D expense | $81.49M | $79.05M | $76.36M | $66.61M | $35.67M |
| SG&A expense | $207.09M | $154.34M | $149.18M | $143.53M | $50.32M |
| Operating income | $469.01M | $551.48M | $337.57M | $267.53M | $275.90M |
| Interest expense | $18.13M | $18.09M | $18.76M | $16.95M | $7.53M |
| Pretax income | $466.88M | $557.13M | $348.33M | $248.92M | $248.52M |
| Income tax | $149.99M | $113.04M | $66.73M | $46.79M | -$154.19M |
| Net income | $316.89M | $444.09M | $281.59M | $202.13M | $402.71M |
| EBITDA | $480.39M | $561.74M | $348.66M | $274.02M | $278.90M |
| EPS (basic) | 2.64 | 3.50 | 2.13 | 1.48 | 2.86 |
| EPS (diluted) | 2.56 | 3.43 | 2.10 | 1.44 | 2.74 |
| Weighted avg. shares (diluted) | 123.90M | 129.42M | 134.20M | 140.61M | 146.80M |
| Balance sheet | |||||
| Cash & equivalents | $133.82M | $115.85M | $118.37M | $234.69M | $119.22M |
| Short-term investments | — | — | — | $128.60M | $622.20M |
| Receivables | $426.27M | $288.20M | $233.25M | $186.97M | $90.97M |
| Inventory | $176.47M | $141.86M | $127.60M | $100.12M | $53.91M |
| Current assets | $825.21M | $1.09B | $746.42M | $739.01M | $926.29M |
| PP&E, net | $44.44M | $40.86M | $38.11M | $35.10M | $6.79M |
| Goodwill | $580.36M | $416.82M | $416.82M | $409.05M | $0 |
| Intangibles | $981.47M | $401.83M | $472.88M | $546.65M | $0 |
| Total assets | $2.53B | $2.06B | $1.73B | $1.84B | $1.10B |
| Current liabilities | $177.09M | $139.10M | $112.49M | $130.79M | $117.15M |
| Short-term debt | $0 | $0 | $0 | $13.33M | $89.42M |
| Long-term debt | $2.14B | $1.51B | $1.50B | $1.49B | $787.25M |
| Total debt | $2.14B | $1.51B | $1.50B | $1.51B | $876.67M |
| Total liabilities | $2.48B | $1.70B | $1.65B | $1.67B | $907.48M |
| Shareholders' equity | $48.81M | $363.82M | $83.81M | $169.80M | $196.95M |
| Net debt | $2.01B | $1.39B | $1.38B | $1.27B | $757.46M |
| Shares outstanding | 117.78M | 123.14M | 126.77M | 135.15M | 137.50M |
| Cash flow statement | |||||
| Operating cash flow | $651.56M | $479.06M | $388.57M | $240.11M | $299.44M |
| Capital expenditure | $6.97M | $10.70M | $15.29M | $4.81M | $1.46M |
| Free cash flow | $644.59M | $468.37M | $373.28M | $235.30M | $297.98M |
| Investing cash flow | -$545.81M | -$262.72M | -$96.91M | -$487.00M | -$406.29M |
| Financing cash flow | -$85.17M | -$218.86M | -$407.99M | $362.37M | $77.86M |
| Depreciation & amortization | $11.39M | $10.26M | $11.08M | $6.49M | $3.00M |
| Stock-based compensation | $51.56M | $43.38M | $36.62M | $24.40M | $20.82M |
| Share buybacks | $342.37M | $250.00M | $402.38M | $200.00M | $350.06M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.